ReviewBreathe (Sheffield, England)2021
The use of treatable traits to address COPD complexity and heterogeneity and to inform the care.
Review in Breathe (Sheffield, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Management of COPD and comorbidities in COPD patients by dispensing pharmaceutical care following Global Initiative for Chronic Obstructive Lung Disease-guidelines (GOLD guidelines 2020): a prospective randomized clinical trial.BMC health services research · 2026Trial
- Can Treatable Traits Be the Approach to Addressing the Complexity and Heterogeneity of COPD?International journal of chronic obstructive pulmonary disease · 2023Trial
- AI in respiratory care: findings from the GOLD report.Journal of translational medicine · 2026Article
- Sociodemographic differences in clinical phenotypes among patients with COPD: a latent class analysis.BMJ open respiratory research · 2026Article
- From clinical phenotypes to cellular mechanisms: a precision medicine framework for COPD.Frontiers in immunology · 2026Review
- Accurate Identification and Intervention System Construction of Treatable Traits in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Protocol for a Randomized Controlled Study.International journal of chronic obstructive pulmonary disease · 2026Article
- Toward precision medicine in COPD: phenotypes, endotypes, biomarkers, and treatable traits.Respiratory research · 2025Review
- Review
- Management of Chronic Obstructive Pulmonary Disease in Vietnam during the COVID-19 Period: Current Situation and Challenges.Tuberculosis and respiratory diseases · 2025Article
- Characterising airway inflammation in Aboriginal and Torres Strait Islander and non-Aboriginal and Torres Strait Islander adults with asthma and COPD.BMJ open respiratory research · 2025Article
- Integrating hot topics and implementation of treatable traits in asthma.The European respiratory journal · 2024Review
- Unravelling the complex interplay of factors behind exercise limitations and physical inactivity in COPD.Breathe (Sheffield, England) · 2024Review
- The treatable traits of asthma in pregnancy: a clinical audit.ERJ open research · 2024Article
- Phenotype to Treatable Traits-Based Management in Chronic Obstructive Pulmonary Disease.Cureus · 2024Review
- From treatable traits to GETomics in airway disease: moving towards clinical practice.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Small airway dysfunction measured by impulse oscillometry is associated with exacerbations and poor symptom control in patients with asthma treated in a tertiary hospital subspecialist airways disease clinic.Frontiers in allergy · 2024Article
- Inhibition of oxidative stress by apocynin attenuated chronic obstructive pulmonary disease progression and vascular injury by cigarette smoke exposure.British journal of pharmacology · 2023Article
- Rational use of inhaled corticosteroids for the treatment of COPD.NPJ primary care respiratory medicine · 2023Review
- Multidisciplinary care in chronic airway diseases: the Newcastle model.ERJ open research · 2022Article
- Targeted therapy in respiratory disease.Breathe (Sheffield, England) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COPD is complex and heterogeneous with respect to its aetiology, clinical presentation, phenotypes and biological mechanisms. Despite this, COPD is still diagnosed and treated according to simple clinical measures, including airflow limitation, symptoms and exacerbation frequency, leading to failure to recognise the disease's heterogeneity and/or to provide targeted interventions. COPD continues to have a very large burden of disease with suboptimal outcomes for people with the disease, including frequent hospitalisation with exacerbations, rapid lung function decline, multimorbidity and death from respiratory failure. In light of this, there have been increasing calls for a renewed taxonomy with better characterisation of COPD phenotypes and endotypes. This would allow the unravelling of COPD's complexity and heterogeneity, the implementation of targeted interventions and improved patient outcomes. The treatable traits strategy is a proposed vehicle for the implementation of precision medicine in chronic airway diseases. In this review, in addition to summarising the key knowledge on the heterogeneity of COPD, we refer to the existing evidence pertaining to the treatable traits strategy as applied in COPD and discuss implementation in different settings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.